DUBLIN--(BUSINESS WIRE)--The "Global Spinal Muscular Atrophy Market: Industry Analysis & Outlook (2019-2026)" report has been added to ResearchAndMarkets.com's offering.
Global Spinal Muscular Atrophy Market: Industry Analysis & Outlook (2019-2026) by the author provides an extensive research and detailed analysis of the present market along with future outlook. Key players i.e. Biogen Inc., Novartis International AG, Roche Holding AG and Cytokinetics, Inc are being profiled along with their respective financials and growth strategies.
Spinal Muscular Atrophy (SMA) is a form of neuromuscular disease that results in loss of lower motor neurons and progressive muscle wasting, often leading to early death. Presently, it affects about 1 in 11,000 babies and about 1 in every 50 Americans is the disease carrier. On the basis of either the onset age of symptoms, SMA is classified into Type I, Type II, Type III and Type IV diseases.
Currently, no specific therapies for cure exist, but certain speciality drugs are expected to enter the market in the year 2019. The clinical care differs with the severity or type of the disorder category.
The global market is expected to witness a lucrative growth due the rising pharmaceuticals research and development (R&D) expenditures, increasing personal healthcare expenditure, accelerating economic growth and growing spinal muscular atrophy occurrence. The market is trending with progressing drug pipeline and high preference for gene therapy. However, there are some growth hindering factors in the market including lethargic drug approval process and associated business risks.
Regionally, the U.S. is expected to hold the leading position in the market, due to the increasing prevalence of motor neuron disorders in the population along with high preference of genetic correction therapy and myostatin drugs.
Key Topics Covered:
1. Market Overview
1.1 Introduction
1.2 Classification
1.3 Causes & Symptoms
1.4 Diagnosis
1.5 Treatment
2. Global Spinal Muscular Atrophy Market
2.1 Global Spinal Muscular Atrophy Market Value Forecast
2.2 Global AVXS-101 Gene Therapy Value Forecast
2.3 Global AVXS-101 Gene Therapy Value Forecast by Region
2.4 Global SRK-015 Drug Value Forecast
2.5 Global SRK-015 Drug Value Forecast by Region
2.6 Global Spinal Muscular Atrophy Incidence by Region
2.7 Global Spinal Muscular Atrophy Prevalence by Region
3. Regional Spinal Muscular Atrophy Market
3.1 The U.S. AVXS-101 Gene Therapy Value Forecast
3.2 The U.S. AVXS-101 Gene Therapy Value Forecast by Disease Type
3.2.1 The U.S. AVXS-101 Gene Therapy Value Forecast by Type I
3.2.2 The U.S. AVXS-101 Gene Therapy Value Forecast by Type II
3.3 The U.S. SRK-015 Drug Value Forecast
3.4 The U.S. SRK-015 Drug Value Forecast by Disease Type
3.4.1 The U.S. SRK-015 Drug Value Forecast by Type I
3.4.2 The U.S. SRK-015 Drug Value Forecast by Type III
3.5 EU AVXS-101 Gene Therapy Value Forecast
3.6 EU AVXS-101 Gene Therapy Value Forecast by Disease Type
3.6.1 EU AVXS-101 Gene Therapy Value Forecast by Type I
3.6.2 EU AVXS-101 Gene Therapy Value Forecast by Type III
3.7 EU SRK-015 Drug Value Forecast
3.8 EU SRK-015 Drug Value Forecast by Disease Type
3.8.1 EU SRK-015 Drug Value Forecast by Type I
3.8.2 EU SRK-015 Drug Value Forecast by Type III
4. Market Dynamics
4.1 Growth Drivers
4.1.1 Rising Pharmaceuticals Research and Development (R&D) Expenditures
4.1.2 Increasing Personal Healthcare Expenditure
4.1.3 Accelerating Economic Growth
4.1.4 Growing Spinal Muscular Atrophy Occurrence
4.2 Key Trends and Developments
4.2.1 Progressing Drug Pipeline
4.2.2 High Preference for Gene Therapy
4.3 Challenges
4.3.1 Lethargic Drug Approval Process
4.3.2 Associated Business Risk
5. Competitive Landscape
5.1 Global Spinal Muscular Atrophy Market
5.1.1 Key Players - Revenue Comparison
5.1.2 Key Players - Drug Features Comparison
5.1.3 Key Players - Market Cap Comparison
6. Company Profiles
- Biogen Inc.
- Cytokinetics, Inc
- Novartis International AG
- Roche Holding AG
For more information about this report visit https://www.researchandmarkets.com/r/damu4w
